Anuh Pharma Limited

ANUHPHR6

INE489G01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-05-31 am EDT			5-day change	1st Jan Change
227.6 ^INR	-0.22%		-2.40%	+55.29%

May. 17	Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
May. 17	Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	CI

Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024

May 17, 2024 at 08:22 am EDT

Anuh Pharma Limited announced that at its board meeting held on 17 May 2024, the board recommended the payment of dividend of INR 2.50 per equity share of face value of INR 5 each (that is 50%) for the financial year ended 31 March 2024, subject to the approval of the Shareholders at the upcoming Annual General Meeting of the Company. register of members and share transfer books of the company will remain closed from 17 August 2024 to 23 August 2024 (both days inclusive) for the purpose of dividend, if approved by members.

Latest news about Anuh Pharma Limited

Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 17	CI
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	May. 17	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023	Apr. 08	CI
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer	Apr. 04	CI
Anuh Pharma Limited Announces Completion of Tenure of Jasvantlal Girdharlal Shah as Independent Director	Apr. 01	CI
Anuh Pharma Gets European Regulator's Nod for Anti-Malarial Drug	Feb. 28	MT
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024	Feb. 12	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 09	CI
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer	Jan. 11	CI
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024	Jan. 05	CI
Anuh Pharma Limited Approves the Board Appointments	Dec. 13	CI
Anuh Pharma Limited Approves Board Appointments	Nov. 10	CI
Anuh Pharma Limited Approves Board Appointments	23-08-19	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Announces Board Changes	23-05-19	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2023	23-05-19	CI
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director	23-02-10	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer	23-01-06	CI
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer	22-10-20	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022	22-08-06	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-05	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022	22-05-14	CI

Chart Anuh Pharma Limited

Duration

Period

More charts

Company Profile

Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ANUH PHARMA LIMITED	+55.29%	137M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B